Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Cymbalta 30 60Cymbalta


1. NAME OF THE MEDICINAL PRODUCT
CYMBALTA 30 mg hard gastro-resistant capsules
CYMBALTA 60 mg hard gastro-resistant capsules


2. QUALITATIVE AND QUANTITATIVE COMPOSITION
The active ingredient in CYMBALTA is duloxetine.
Each Cymbalta 30 mg & 60 mg capsule contains 30 mg & 60 mg of duloxetine as duloxetine hydrochloride respectively.

For excipients. see section 6.1.


3. PHARMACEUTICAL FORM
Hard gastro-resistant capsule.
The CYMBALTA 30 mg capsule has an opaque white body, imprinted with '30 mg' and an opaque blue cap, imprinted with '9543'.

The CYMBALTA 60 mg capsule has an opaque green body, imprinted with '60 mg' and an opaque blue cap, imprinted with '9542'.

 

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of major depressive disorder.
Management of neuropathic pain associated with diabetic peripheral neuropathy in adults.
Treatment of generalized anxiety disorder.


4.2 Posology and method of administration
For oral use.
Major Depressive Disorder
The starting and recommended maintenance dose is 60 mg once daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations.


Therapeutic response is usually seen after 2-4 weeks of treatment.


After consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse.
 

Diabetic Peripheral Neuropathic Pain
Cymbalta should be administered at a dose of 60 mg once daily with or without food. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. The plasma concentration of duloxetine displays large inter-individual variability (see section 5.2). Hence, some patients that respond insufficiently to 60 mg may benefit from a higher dose.


The medicinal product response should be evaluated after 2 months' of treatment. Additional response after this time is unlikely (see section 5.1).


The therapeutic benefit should regularly (at least every three months) be reassessed.


Generalized Anxiety Disorder
Duloxetine should be administered at a dose of 60 mg once daily without regard to meals.


For some patients, it may be desirable to start at 30 mg once daily for one week to allow patients to adjust to medication before increasing to 60 mg once daily. While a 120 mg once daily was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit. Nevertheless, if a decision is made to increase the dose beyond 60 mg once daily. dose increases should be in increments of 30 mg once daily. The safety of doses above 120 mg once daily has not been adequately evaluated.

 

Special Populations and General Information:
Hepatic impairment

CYMBALTA should not be used in patients with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2).

 

Renal insufficiency
No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml, min). See section 4.3 for severe renal impairment.


Elderly
Major Depressive Disorder: Depression may have different features in the elderly which make it difficult to extrapolate efficacy and safety data from a younger population. Only limited clinical data on the use of CYMBALTA in elderly patients with major depressive disorders is available. Therefore, caution should be exercised when treating the elderly. Until more efficacy data are available the use of CYMBALTA in the very elderly population (>75 years) is not recommended. (see sections 4.4 and 5.2).

 

Diabetic Peripheral Neurophatic Pain: No dosage adjustment is recommended for elderly patients solely on the basis of age. However, caution should be exercised when treating the elderly (see section 5.2)


Children and adolescents
The safety and efficacy of duloxetine in these age groups have not been studied. Therefore, administration of CYMBALTA to children and adolescents is not recommended (see section 4.4).


Discontinuation of treatment
Abrupt discontinuation should be avoided. When stopping treatment with CYMBALTA the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently. the physician may continue decreasing the dose, but at a more gradual rate.

 

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients.


Concomitant use of CYMBALTA with nonselective, irreversible Monoamine Oxidase Inhibitors (MAOIs) is contraindicated (see section 4.5).


Liver disease resulting in hepatic impairment (see section 5.2).


CYMBALTA should not be used in combination with fluvoxamine. ciprofloxacin or enoxacine (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
Severe renal impairment (creatinine clearance <30 ml/min).


In clinical trials. Cymbalta use was associated with an increased risk of mydriasis; therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma.


The initiation of treatment with CYMBALTA is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and 4.8).

 

1    2    3    4    5    6    7

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer